What the trial was testing
The CLARITY-AD enrolled 1,795 patients with alzheimer's disease. The study was sponsored by Eisai and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
27% slower decline in memory and daily function over 18 months.
New England Journal of Medicine · 2023 · NCT03887455
These findings — that in memory and daily function over 18 months for people with early Alzheimer's — were published in the New England Journal of Medicine and represent the headline result of the study.
Researchers tracked outcomes across 1,795 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with alzheimer's disease, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Lecanemab (Leqembi) is FDA-approved and available now for people with early Alzheimer's or mild cognitive impairment caused by Alzheimer's. Eligibility requires confirmed amyloid in the brain, usually with a PET scan or spinal fluid test. Brain swelling and small bleeds are real risks, so most centers screen for the APOE4 gene before starting. Ask a neurologist if you qualify.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open alzheimer's disease trials
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
To identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD).
Establishment of the Chinese Preclinical Alzheimer's Disease Study With Multiple Neuroimaging
The goal of this observational study is to investigate neuroimage and biomarkers in the Alzheimer's continuum in Chinese population. We aimed to: * To reveal the progress of AD by multiple neuroimage and biomarkers; * To reveal the longitudinal change of biomarkers and cognition of AD in Chinese population; * To investigate the interaction of markers between body and brain; * To set up new markers by neuroimage.